

IARC Handbooks of Cancer Prevention
Cervical Cancer Screening, Volume 10 (2005)

Type of evaluation	Agent	Evidence
Efficacy	Screening by conventional cytology	<i>Sufficient</i>
	Screening by liquid-based cytology	<i>Sufficient</i>
	Screening by automated cytology	<i>Sufficient</i>
	Testing for human papillomavirus infection as the primary screening modality	<i>Sufficient</i>
	Screening by visual inspection with application of acetic acid (VIA)	<i>Limited</i>
	Screening by visual inspection with application of Lugol's iodine (VILI)	<i>Limited</i>
Overall	Screening by conventional cytology, every 3–5 years between the ages of 35 and 64 years, in a high-quality programme	<i>Sufficient</i>
	HPV testing, using a validated system, as the primary screening modality	<i>Sufficient</i>
	Screening by visual inspection with application of acetic acid (VIA) or with Lugol's iodine (VILI)	<i>Limited</i>